CClinicalTrials.gg
CompletedNCT03278301Updated Oct 19, 2020

PRECISION GRX Registry

An observational study in Coronary Artery Disease, sponsored by Corindus Inc.. Completed at 20 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by Corindus Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
952
Ages
18 Years and older
Sex
All
01

Study summary

To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath GRX System, in the delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.

Read the detailed description

This is a single-arm, open-label, multi-center patient registry of the CorPath GRX System to examine its performance during PCI procedures and patient outcomes through 72 hours post-procedure or hospital discharge, whichever occurs first.

02

Conditions studied

  • Coronary Artery Disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects with coronary artery disease and with a clinical indication for PCI.

Inclusion criteria

Candidates will be included in the study only if all of the following conditions are met:

  1. Age ≥18 years;
  2. Patients with coronary artery disease with clinical indication for PCI;
  3. Patient deemed appropriate for robotic-assisted PCI; and
  4. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Candidates will be excluded from the study if any of the following conditions are present:

    1. Failure/inability/unwillingness to provide informed consent; or
    2. The investigator determines that the patient or the coronary anatomy is not suitable for robotic-assisted PCI.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
952 participants (actual)
Target follow-up
3 Days
Patient registry
Yes

Interventions

  • DeviceRobotic-assisted PCI

    The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.

05

What researchers measure

Primary outcomes

  1. Clinical Success

    Less than 30% residual stenosis (visual estimate) post PCI in the lesion(s) treated with the CorPath GRX System, without in-hospital major adverse coronary events (MACE).

    Time frame: Discharge or 72 hours post intervention, whichever comes first.

  2. Technical Success

    Defined as successful completion of the robotic-assisted PCI absent unplanned conversion to manual for guidewire or balloon/stent catheter inability to navigate vessel anatomy or poor guide catheter support.

    Time frame: Procedure

Secondary outcomes

  1. Overall Procedure Time

    Defined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.

    Time frame: Procedure

  2. PCI Procedure Time

    Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter.

    Time frame: Procedure

  3. Fluoroscopy Time

    Total Fluoroscopy Time during procedure will be captured.

    Time frame: Procedure

  4. Patient Radiation Exposure

    DAP (dose-area-product) and cumulative dose/air kerma as recorded during the procedure.

    Time frame: Procedure

06

Study locations

20 sites
  • UC San Diego Health Sulpizio Cardiovascular Center
    San Diego, California 92037, United States
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Spectrum Health Hospitals Fred and Lena Meijer Heart Center
    Grand Rapids, Michigan 49503, United States
  • William Beaumont Hospital - Troy
    Troy, Michigan 48085, United States
  • St. Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • New York-Presbyterian Columbia University Medical Center
    New York, New York 10032, United States
  • WakeMed Raleigh Campus
    Raleigh, North Carolina 27610, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Wellspan York Hospital
    York, Pennsylvania 17405, United States
  • Jackson-Madison County General Hospital
    Jackson, Tennessee 38301, United States
  • Baylor Jack and Jane Hamilton Heart and Vascular Hospital
    Dallas, Texas 75226, United States
  • Baylor Scott and White All Saints Medical Center
    Fort Worth, Texas 76104, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • The Heart Hospital Baylor Plano
    Plano, Texas 75093, United States
  • University of Virginia Health System University Hospital
    Charlottesville, Virginia 22903, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Albert Einstein Israelite Hospital
    São Paulo, Sao Paulo 05652-900, Brazil
  • Apex Heart Institute
    Ahmedabad, Gujarat 380059, India
  • Tan Tock Seng Hospital
    Singapore, 308433, Singapore
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03278301
Lead sponsor
Corindus Inc.
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
Aug 27, 2017
Primary completion
Feb 6, 2020
Completion
Feb 6, 2020
Last update
Oct 19, 2020

Study contacts

Ehtisham Mahmud, MD
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion